Physician profile
Marietta E Go
NPI 1801113683
$2,123.08
in general payments reported to CMS, 2019-2025
32 companies · $786 in 2025
The $786 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.44 · 2020: $97.81 · 2021: $205 · 2022: $186 · 2023: $318 · 2024: $489 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.93 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $309.81 | 2020-2025 | |
| Glaxosmithkline, LLC. | $147.46 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.78 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $107.75 | 2024 | |
| Ardelyx, INC. | $104.98 | 2024-2025 | Ibsrela |
| Exact Sciences Corporation | $102.72 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $102.64 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $98.83 | 2023 | Veozah |
| Novo Nordisk INC | $87.09 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $79.74 | 2019-2024 | Farxiga, Breztri |
| Sumitomo Pharma America, INC. | $79.36 | 2024-2025 | Gemtesa |
| Aimmune Therapeutics, INC. | $75.01 | 2024-2025 | Zenpep |
| Baxter Healthcare | $74.05 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Abbott Laboratories | $71.02 | 2023-2025 | Freestyle Libre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.87 | 2021-2024 | Xifaxan |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $52.05 | 2021-2022 | |
| Pfizer INC. | $46.74 | 2023-2024 | |
| Amgen INC. | $44.01 | 2023 | Repatha, Otezla |
| Cumberland Pharmaceuticals, INC. | $42.76 | 2025 | Kristalose |
| Avanir Pharmaceuticals, INC. | $42.25 | 2019-2020 | |
| Shield Therapeutics INC | $32.33 | 2023-2024 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $32.01 | 2023-2025 | |
| Lundbeck LLC | $27.09 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $24.49 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.86 | 2022 | |
| Evoke Pharma, INC. | $22.53 | 2021 | |
| Dexcom, INC. | $21.39 | 2025 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $20.52 | 2021 | |
| Amarin Pharma, INC. | $17.73 | 2022 | |
| Medtronic, INC. | $17.61 | 2021 | |
| Merck Sharp & Dohme LLC | $14.90 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marietta Go listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.